Monozygotic twins with DYT-TOR1A showing jerking movements and levodopa responsiveness

Brain Dev. 2021 Aug;43(7):783-788. doi: 10.1016/j.braindev.2021.03.005. Epub 2021 Apr 5.

Abstract

Background: DYT-TOR1A is caused by a GAG deletion in the TOR1A gene. While it usually manifests as early-onset dystonia, its phenotype is extremely diverse, even within one family. Recent reports have revealed that some DYT-TOR1A cases have novel mutations in the TOR1A gene while others have mutations in both TOR1A and another DYT gene (THAP1 or SGCE). Our understanding of the correlation between genotype and phenotype is becoming increasingly complicated.

Case presentations: Here, we report on monozygotic twins who developed dystonia in childhood. The two children had different presentations in terms of onset age and dominant disturbances, but both exhibited marked diurnal fluctuation and jerking movements of the limbs as well as levodopa/levodopa-carbidopa responsiveness. These features are commonly associated with DYT/PARK-GCH1 and DYT-SGCE, yet these twins had no mutations in the GCH1 or SGCE genes. Whole exome sequencing eventually revealed a single GAG deletion in the TOR1A gene.

Conclusion: Monozygotic twins whose only mutation was a GAG deletion in TOR1A exhibited DYT/PARK-GCH1-asssociated features and jerking movements reminiscent of myoclonus. This finding may expand the spectrum of phenotypes associated with DYT-TOR1A, and suggests that levodopa has potential as a treatment for DYT-TOR1A with DYT/PARK-GCH1-associated features.

Keywords: DYT-TOR1A; Jerking movements; Levodopa responsiveness; Monozygotic twins.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Carbidopa / pharmacology
  • Dopamine Agents / pharmacology*
  • Drug Combinations
  • Dystonic Disorders* / drug therapy
  • Dystonic Disorders* / genetics
  • Dystonic Disorders* / physiopathology
  • Humans
  • Levodopa / pharmacology*
  • Male
  • Molecular Chaperones / genetics*
  • Twins, Monozygotic

Substances

  • Dopamine Agents
  • Drug Combinations
  • Molecular Chaperones
  • TOR1A protein, human
  • carbidopa, levodopa drug combination
  • Levodopa
  • Carbidopa